Get started
Author

Cynthia R. C. Osborne

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
2017 · Miguel Martin, Frankie A Holmes, et al. · The Lancet Oncology · 587
Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial
2009 · J. O'Shaughnessy, C. Osborne, et al. · Journal of Clinical Oncology · 242
Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
2012 · David W. Craig, Joyce A. O'Shaughnessy, et al. · Molecular Cancer Therapeutics · 220
uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues
2006 · Songdong Meng, Debu Tripathy, et al. · Proceedings of the National Academy of Sciences · 158
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer
2020 · Jennifer R. Diamond, Carlos Becerra, et al. · Breast Cancer Research and Treatment · 153
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis
2022 · Guy Jerusalem, Yeon Hee Park, et al. · Cancer Discovery · 107
PDF
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer
2021 · Aditya Bardia, Virginia Kaklamani, et al. · Journal of Clinical Oncology · 105
PDF
Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies
2015 · Haralambos Raftopoulos, Abderrahmane Laadem, et al. · Supportive Care in Cancer · 68
PDF
Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling
2013 · Frankie Ann Holmes, Virginia Espina, et al. · BMC Research Notes · 67
PDF
Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.
2021 · Guy Heinrich Maria Jerusalem, Yeon Hee Park, et al. · Journal of Clinical Oncology · 52
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study
2024 · Komal L. Jhaveri, Elgene Lim, et al. · Journal of Clinical Oncology · 49
PDF
Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update
2011 · Reva Schneider, Ayman Barakat, et al. · Breast Cancer Targets and Therapy · 41
PDF
Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study
2016 · Denise A. Yardley, James Reeves, et al. · Clinical Breast Cancer · 35
Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with paclitaxel (P) in patients (pts) with 1st- to 3rd-line metastatic HER2-negative breast cancer (BC).
2016 · Monica M. Mita, Carlos Becerra, et al. · Journal of Clinical Oncology · 25
Final results of a phase 2 study of ramucirumab (RAM) plus eribulin (E) versus E in advanced metastatic breast cancer (MBC).
2014 · Denise A. Yardley, Paul D. Richards, et al. · Journal of Clinical Oncology · 16
Abstract P3-11-03: A randomized, phase 2 trial of preoperative MM-121 with paclitaxel in triple negative (TN) and hormone receptor (HR) positive, HER2-negative breast cancer
2015 · Frankie A Holmes, Kristi J McIntyre, et al. · Cancer Research · 14
The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer
2009 · Cynthia R. Osborne, Anita Duncan, et al. · Breast Cancer Research and Treatment · 14
Abstract PD7-07: Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer
2020 · Virginia Kaklamani, Aditya Bardia, et al. · Cancer Research · 13
Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients
2019 · Devchand Paul, Svetislava J. Vukelja, et al. · npj Breast Cancer · 13
PDF
MammaPrint predicts chemotherapy benefit in HR+HER2- early breast cancer: FLEX Registry real-world data
2025 · Adam M Brufsky, Kent F Hoskins, et al. · JNCI Cancer Spectrum · 12
PDF
Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer.
2024 · Erin Frances Cobain, Lajos Pusztai, et al. · Journal of Clinical Oncology · 12
PDF
Preliminary safety and activity results of trabectedin in a phase II trial dedicated to triple-negative (ER-, PR-, HER2-), HER2+++, or BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts)
2009 · S. Delaloge, K. L. Tedesco, et al. · Journal of Clinical Oncology · 11
Abstract PD13-12: PD13-12 Imlunestrant, an oral selective estrogen receptor degrader, in combination with abemaciclib with or without an aromatase inhibitor, in estrogen receptor-positive advanced breast cancer: Results from the phase 1a/b EMBER study
2023 · Komal Jhaveri, Hwei-Chung Wang, et al. · Cancer Research · 10
Final analysis of phase II study of EZN-2208 (PEG-SN38) in metastatic breast cancer (MBC).
2012 · Cynthia R. C. Osborne, Joyce O'Shaughnessy, et al. · Journal of Clinical Oncology · 10
G2 Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial
2009 · J. O'Shaughnessy, C. Osborne, et al. · European Journal of Cancer Supplements · 10
Works count: 75
Citation count: 2,085
H-index: 15
I10-index: 25
Year
Topic
Type